Similar companies
Income Statement (USD)
| Q4 '25 | QoQ | |
|---|---|---|
| Revenue | 1.26B | 4.2% |
| Gross Profit | 793M | 8.4% |
| Cost of Revenue | 467M | 2.3% |
| Operating expense | 470M | 3.9% |
| Net Income | 267M | 5.8% |
| EBITDA | 388M | 7.7% |
Balance Sheet (USD)
| Q4 '25 | QoQ | |
|---|---|---|
| Total Assets | 6.34B | 15.5% |
| Total Liabilities | 3.59B | 24.7% |
| Total Equity | 2.75B | 0.7% |
| Shares Outstanding | 399M | 2.1% |
Cash Flow (USD)
| Q4 '25 | QoQ | |
|---|---|---|
| Cash from operations | 294M | 55.4% |
| Cash from financing | -1.52B | 769.8% |
EPS
Financial Highlights for Dexcom in Q4 '25
Dexcom reported a revenue of 1.26B, which is a 4.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 793M, marking a 8.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 467M, a -2.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 470M, showing a -3.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 267M, showing a -5.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 388M, showing a -7.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Dexcom faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. A decline in EBITDA signals potential operational challenges or increased costs.
